Indriyam Biologics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth 36.24%
- Profit Growth -125.82%
- Ebitda -84.10%
- Net Worth -145.95%
- Total Assets -92.52%
About Indriyam Biologics
Indriyam Biologics Private Limited (IBPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 May 2017 (Seven years and eight months 23 days old ). Its registered office is in Alappuzha, Kerala, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dileep Nair and Anaswara Sulochana serve as directors at the Company.
Company Details
-
Location
Alappuzha, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85320KL2017PTC049104
-
Company No.
049104
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 May 2017
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Indriyam Biologics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dileep Nair
|
Director | 11-May-2017 | Current |
|
Anaswara Sulochana
|
Director | 11-May-2017 | Current |
Financial Performance of Indriyam Biologics.
Indriyam Biologics Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 36.24% increase. The company also saw a substantial fall in profitability, with a 125.82% decrease in profit. The company's net worth observed a substantial decline by a decrease of 145.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indriyam Biologics?
In 2020, Indriyam Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Scinova Solutions Private LimitedDileep Nair is a mutual person
-
Breathelife Biosciences Private Limited
Dileep Nair is a mutual person
-
Edgeai Private Limited
Dileep Nair is a mutual person
-
D2sbiosolutions Private Limited
Dileep Nair is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Indriyam Biologics?
Unlock and access historical data on people associated with Indriyam Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indriyam Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indriyam Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.